Monday, October 3, 2022


Biotechnology News Magazine

Scandinavian ChemoTech’s Subsidiary Signs 1st Commercial Contract for the US Veterinary Market

ChemoTech's Animal Care division Vetiqure AB signs a contract with FloridaWild Veterinary Hospital ("FloridaWild") in Deland, Florida as a direct result of a successful trade show in Orlando, which generated many leads

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ChemoTech: The contract with FloridaWild includes access to our vetIQure™ TSE device during an initial evaluation period and a commercial purchase of our treatment kits. In addition to the purchase of the treatment kits an order for the device will be placed following a successful evaluation.

The joint goal with the agreement is to establish a Centre of Excellence with FloridaWild where clinical data and protocols for different species can be found and evaluated notes ChemoTech.

This agreement is a result from the VMX 2022 trade show in Orlando Florida, where Vetiqure AB presented the vetIQure™ and its patented TSE technology. FloridaWild is a veterinary hospital well known for its holistic and innovative perspective on Animal Care. An excellent fit for the first commercial installation for our unique and innovative TSE technology.

“We are very pleased to partner with Vetiqure to contribute to the body of evidence and work toward our shared goal of developing innovative therapies to help pets live their best lives.”- says Dr. Pamela Schrager, Medical Director, FloridaWild Veterinary Hospital.

“The traction we have in the US at the moment and the interest we’ve received from other countries is very promising. Growth potentials like this will allow us to improve and expand our production capacity and our logistics to match the increased demand. We will now allocate resources to our Animal Care business in the US, Europe and the Middle East to ensure that we take full advantage of the commercial and clinical opportunities in front of us.”  – says Mohan Frick, CEO ChemoTech & Vetiqure.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine